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Glycoprotein VI (GPVI) has a crucial role in platelet
responses to collagen. Still, little is known about its
interaction with its ligands. In binding assays using sol-
uble or cell-expressed human GPVI, we observed that (i)
collagen, and the GPVI-specific ligands collagen-related
peptides (CRP) and convulxin, competed with one an-
other for the binding to GPVI and (ii) monoclonal anti-
bodies directed against the extracellular part of the hu-
man receptor displayed selective inhibitory properties
on GPVI interaction with its ligands. Monoclonal anti-
body 9E18 strongly reduced the binding of GPVI to col-
lagen/CRP, 3F8 inhibited its interaction with convulxin,
whereas 9O12 prevented all three interactions. These
observations suggest that ligand-binding sites are dis-
tinct, exhibiting specific features but at the same time
also sharing some common residues participating in the
recognition of these ligands. The epitope of 9O12 was
mapped by phage display, along with molecular model-
ing of human GPVI, which allowed the identification of
residues within GPVI potentially involved in ligand rec-
ognition. Site-directed mutagenesis revealed that valine
34 and leucine 36 are critical for GPVI interaction with
collagen and CRP. The loop might thus be part of a
collagen/CRP-binding site.
Platelet interaction with a damaged vessel wall initiates
thrombus formation. Collagen is the main component of the
subendothelial matrix allowing platelet adhesion and activa-
tion. Several collagen receptors are involved in this process (1).
Among them, glycoprotein VI (GPVI)1 plays a crucial role in
platelet responses to collagen. GPVI belongs to the immuno-
globulin superfamily of receptors (2, 3) and is expressed at the
platelet surface as a non-covalent complex with its signaling
subunit, the common  chain of immunoreceptors (FcR) (3, 4).
In addition to fibrous collagen, two specific agonists are used to
study GPVI function: the synthetic, triple-helical, collagen-
related peptides (CRP) based on a repeated GPOmotif (glycine-
proline-hydroxyproline) (5) and convulxin, a multimeric, C-
type lectin-like toxin from the venom of a rattlesnake (6, 7).
The signaling pathway of GPVI is analogous to that of
immune receptors; it involves a cascade of Tyr phosphoryla-
tion by Src family kinases and the association of the adaptor
protein LAT with phosphatidylinositol 3-kinase. It eventu-
ally leads to phospholipase C2 activation, increase in intra-
cellular calcium concentration, and platelet activation (8).
GPVI participates in stable platelet adhesion to subendothe-
lial collagen and is responsible for collagen-induced platelet
activation, leading to platelet aggregation and anionic phos-
pholipid exposure, thus providing a procoagulant surface for
thrombin formation (9–12).
GPVI shares a high degree of homology with the low affinity
IgA receptor FcRI and killer cell inhibitory receptors (KIRs)
(2). The genes encoding these receptors are located on the same
chromosome (19q13.4) within the leukocyte receptor cluster
(13). The extracellular (EC) domain of GPVI contains two Ig-
like loops of the C2 type. The EC1 N-terminal loop is of the
IgC2-1 type, as is the EC1 domain of FcRI, whereas the GPVI
EC2 loop is of the IgC2-2 subtype found in KIRs (13). The
respective role of EC1, EC2, and the interdomain region varies
from one receptor of the leukocyte receptor cluster family to
another. The IgA-binding site has been shown to involve struc-
tures located in the EC1 domain of FcRI (14). KIR family
members bind their ligand HLA in the hinge, interdomain
region (15), whereas FcRI and FcRII bind their ligand via
their EC2 membrane proximal domain (16).
To locate ligand-binding site(s) on human GPVI, we have
produced a panel of monoclonal antibodies (mAbs) directed
against the extracellular part of human GPVI. Their ability to
prevent GPVI interactions with collagen, CRP, and convulxin
was measured in a binding assay using purified proteins and in
a cell adhesion assay. The results indicate that the binding
sites on GPVI for the diverse ligands seem to be distinct,
exhibiting specific features but at the same time also sharing
some common residues participating in the recognition of these
ligands. Furthermore, we have previously characterized mAb
9O12 as a potent antagonist of GPVI function in vitro (17).
Using phage display, we have identified its epitope within the
GPVI structure. Site-directed mutagenesis has been performed
on a soluble form of the receptor. The characterization of the
GPVI mutants showed that a loop of the EC1 domain partici-
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Prostaglandin E1, grade VII apyrase, ortho-phenylenediamine dihy-
drochloride, para-nitrophenylphosphate disodium salt, horseradish
peroxidase (HRP)-coupled streptavidin, and polyoxyethylenesorbitan
monolaurate (Tween 20) were from Sigma, bovine serum albumin Cohn
fraction V was from Research Organics Inc. (Cleveland, OH), and poly-
clonal anti-phage M13 antibody-HRP was from Amersham Biosciences.
Goat anti-mouse-HRP was from Jackson ImmunoResearch Laborato-
ries (West Grove, PA).
Collagen type I from equine tendon (Horm collagen) came from
Nycomed (Munich, Germany). Convulxin was purified from the venom
of Crotalus durrissus terrificus (Latoxan, France) as described (6). CRP
were a generous gift from Dr. R. Farndale (Cambridge, UK) (18).
The pentadecamer phage display peptide library was a kind gift of
Dr. G. Smith (University of Missouri, Columbia, MO). Monoclonal an-
tibodies were biotinylated using N-hydroxysuccinimide-LC-Biotin
(Pierce) according to the manufacturer’s instructions.
The human hematopoietic HEL cell line was engineered to express
full-length human GPVI (rGPVI-HEL), as reported (3).
Anti-human GPVI Monoclonal Antibodies
The negative isotype-matched control antibody (7I20) and mAbs
9O12, 9E18, and 3F8, directed against the extracellular part of human
GPVI, were produced and purified by affinity chromatography on Hi-
Trap protein A-Sepharose, as described (3, 17). As shown previously for
9O12 (17), the newly characterized 9E18 and 3F8 bind to human plate-
lets as measured by flow cytometry and label a 58-kDa band corre-
sponding to GPVI in Western blot analysis of human platelet proteins
but do not recognize GPVI under reducing conditions, Also, their IgGs
induce aggregation of human platelets with threshold concentration5
g/ml.
Wild Type and Mutant Recombinant Soluble Human GPVI
The cDNA of the recombinant soluble human GPVI (rsGPVI-Fc) was
designed and produced as described (3). Residues Gly-30, Val-34, and
Leu-36 of rsGPVI-Fc were altered to an alanine using the QuikChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA). The sense
oligonucleotides of the mutagenic pairs were as follows: 5-ACCTCCG-
GGCGCGGACCTGTACCGC-3, V34A; 5-CCGGGCGTGGACGCGTA-
CCGCCTGGAG-3, L36A; 5-CCTCCGGTGCCAGGCACCTCCGGGCG-
CGGACGCGTACCGCCTGGA-3, G30A-V34A-L36A. Mutant con-
structs were confirmed by sequencing. Wild type (WT) and mutant
rsGPVI-Fc were produced as already reported (3) and purified by affin-
ity chromatography on HiTrap protein A-Sepharose. Purity was
checked by SDS-PAGE.
Isolation of Phages Binding to 9O12 mAb
To identify the epitope of 9O12, a linear pentadecamer phage display
library was used, essentially as described elsewhere (19). Biotinylated
9O12 (10 g) was incubated with phages in low ionic strength buffer,
0.5% Tween 20. Streptavidin-coated magnetic beads (Dynal, Oslo, Nor-
way) were added to the mixture. After five steps of washing in LIB, 0.5%
Tween 20, bound phages were eluted with 0.1 M glycine, pH 2. Phages
were amplified by infection of Escherichia coli K91 Kan cells and
partially purified from the supernatant by polyethylene glycol precipi-
tation. Two additional rounds of panning were performed, and after
each round, phages were amplified. A dilution of the final eluted phage
pool was plated on Luria broth agar plates containing tetracycline.
Single colonies were picked from these plates and grown overnight in
2 TY medium containing tetracycline in a 96-well plate. After centrif-
ugation of the plates, 9O12-binding phages contained in the superna-
tant were detected in ELISA. Phage DNA was prepared by phenol/
chloroform extraction for sequencing.
SDS-PAGE and Immunoblotting
Proteins from phages were separated on a 10% acrylamide slab gel,
under non-reducing and reducing conditions, and blotted on a nitrocel-
lulose membrane (Amersham Biosciences). After blocking with a 5%
milk powder solution, the membrane was incubated with biotinylated
9O12 (2 g/ml in PBS, 0.4% milk powder) for 2 h. The membrane was
washed with PBS containing 0.05% Tween 80 before a 2-h incubation
with streptavidin-HRP. The membrane was developed using the ECL
detection system (Amersham Biosciences).
ELISA and Binding Assays Using Purified Proteins
Measurement of Phage Binding to 9O12—Purified 9O12 (10 g/ml in
PBS) was coated overnight in a 96-well plate. After blocking with a 2%
milk powder solution, dilution series of the individual phage clones
selected after the final panning round were added to the wells (all in
PBS, 0.2% milk powder). An irrelevant phage that specifically binds to
von Willebrand factor (20) was used as a negative control. Phages were
incubated at room temperature for 90 min. After washing with PBS,
0.1% Tween 20, a polyclonal anti-M13-HRP-conjugated antibody was
added to the wells and incubated for 1 h. Bound phages were detected,
after washing, by hydrolysis of ortho-phenylenediamine dihydrochlo-
ride. Alternatively, phages were preincubated 30 min with increasing
doses of rsGPVI-Fc before addition to the 9O12-containing wells.
Binding of rsGPVI-Fc (WT and mutants) to Collagen, CRP or Con-
vulxin—Experiments were conducted mainly as described (17); microti-
tration wells were coated overnight with collagen type I, CRP, or con-
vulxin, in PBS, and blocked with 0.2% BSA for 2 h. WT or mutant
rsGPVI-Fc (in PBS, 0.1% BSA, 0.1% Tween 20) were added to the wells
and incubated for 2 h. Alternatively, rsGPVI-Fc was preincubated for 30
min with 10 g/ml anti-GPVI mAb before addition to the wells. After
washing with PBS, 0.1% BSA, 0.1% Tween 20, bound rsGPVI-Fc was
detected using HRP-coupled protein A or HRP-coupled goat anti-mouse
antibody, as indicated. To study the binding of convulxin to rsGPVI-Fc,
microtitration wells were coated with a non-blocking anti-GPVI mAb
(1P10, 5 g/ml) and saturated with BSA. 0.5 nM rsGPVI-Fc (in PBS,
0.2% BSA, 0.1% Tween 20) was added for 2 h at room temperature.
After washing, immobilized rsGPVI-Fc was incubated 45 min with
anti-GPVI mAbs or buffer, and then 125I-convulxin was added, and
incubation was prolonged for 10 min. Wells were washed with PBS,
0.2% BSA, 0.1% Tween 20 and counted for 125I-convulxin in a -counter.
Cell Adhesion Assay and Preparation of Human Platelets
Experiments were mainly performed as described previously (3, 21).
Microtitration wells were coated with collagen type I, convulxin, or CRP
(20 g/ml each in PBS). After blocking with BSA, rGPVI-HEL cells
(5.106/ml) in Tyrode-Hepes buffer were added to the wells and allowed
to adhere for 1 h under gentle agitation. For competition studies, cells
were preincubated for 30 min with increasing doses of collagen, CRP, or
convulxin before adhesion. Adherent cells were quantified by meas-
uring alkaline phosphatase activity using para-nitrophenylphosphate
disodium salt. Human washed platelets (3.108/ml) were prepared ac-
cording to a previously described procedure (7).
Homology Modeling of GPVI
A three-dimensional model of the extracellular domain of human
GPVI was built by comparative modeling using the 2.1-Å x-ray struc-
ture of the first two Ig-like domains of human LIR-1 (Protein Data Bank
code 1G0X (22)) as template. The sequences of the extracellular domain
of human GPVI and the crystallized ligand-binding domain of LIR-1
were first aligned using the Clustal algorithm (23). The quality of the
final alignment was evaluated by identity (48%) and homology score
(77%). The resulting alignment was used as input for Modeler v6.0
(salilab.org/modeler) (24). Several three-dimensional structures were
generated (n  20) and evaluated using the Modeler objective function.
Root mean square deviation was inferior to 0.3 Å. Only the first model
was used.
Statistical Analysis
Data are expressed as mean  S.E. Student’s t test or one-factor
analysis of variance followed by the Bonferroni test was used to evalu-
ate statistical significance. A value of p  0.05 was considered to be
statistically significant.
RESULTS
Competition between Collagen, CRP, and Convulxin for the
Binding to Cell-expressed GPVI—The hematopoietic cell line
HEL was engineered to overexpress recombinant human GPVI
(rGPVI) (3). rGPVI associated with FcR. Equilibrium binding
studies indicated that 125I-labeled convulxin bound to 65,000
sites with a Kd of 0.35 nM on GPVI-transduced cells versus
11,000 sites with a similar Kd on mock-transduced cells. Con-
vulxin induced intracellular calcium mobilization in rGPVI-
HEL (not shown). In addition, rGPVI-HEL cells were able to
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adhere to immobilized collagen, CRP, and convulxin in a time-
and dose-dependent manner (17). rGPVI-HEL expressed a low
level of integrin 21 at their surface as indicated by flow
cytometry using a fluorescein isothiocyanate-coupled anti-
CD49b. We investigated the ability of collagen, CRP, and con-
vulxin to compete with one another for the binding to cell-
expressed GPVI by studying the adhesion of rGPVI-HEL to the
coated ligand in the presence of the others in soluble form.
Cell adhesion to collagen was reduced by increasing amounts
of convulxin; maximal inhibition reached 88% with 0.5 nM
convulxin, and the IC50 was 0.08 nM (Fig. 1A). CRP had a
moderate inhibitory effect on the adhesion of rGPVI-HEL to
collagen. 2.5 g/ml CRP decreased adhesion by 40%, and 10-
fold higher concentrations did not further inhibit the binding to
collagen (not shown).
Adhesion of rGPVI-HEL to convulxin was abolished by in-
creasing amounts of collagen. The IC50 was 10 g/ml, and 95%
inhibition was reached with 50 g/ml collagen (Fig. 1B). In
contrast, 50 g/ml CRP only reduced adhesion to convulxin by
20%, but 2.5 g/ml was sufficient to reach the maximal inhib-
itory effect (not shown). Adhesion to CRP was fully inhibited by
both collagen and convulxin. 95% inhibition was reached with
10 g/ml collagen (IC50  2.5 g/ml) (Fig. 1D), whereas the
maximal effect was obtained with 0.25 nM convulxin (IC50 
0.06 nM) (Fig. 1C). These results demonstrate that collagen and
convulxin, and to a lesser extent CRP, compete with each other
for the binding to cell-expressed rGPVI.
Identification of Selective Antagonists of GPVI Interaction
with Its Ligands—To further characterize ligand-binding sites
on human GPVI, we have tested the ability of several mAbs
directed against the extracellular domain of the receptor to
inhibit the interaction of a recombinant soluble form of GPVI
(rsGPVI-Fc) with its ligands collagen, CRP, and convulxin. One
of them, 9O12, prevented the interaction of GPVI with both
collagen and convulxin (17) (Fig. 2). The binding of rsGPVI-Fc
to immobilized collagen was markedly inhibited by 9O12, with
an IC50 of 1.5 g/ml, and 20 g/ml antibody yielded an inhibi-
tion of 85%. The binding of convulxin to immobilized rsGPVI-Fc
was strongly reduced by the antibody; the maximal inhibition
reached 80% for concentrations of 9O12 above 10 g/ml, and
the IC50 was 3 g/ml. In addition, 10 g/ml 9O12 abolished the
binding of rsGPVI-Fc to CRP.
The effect of other mAbs on the binding of rsGPVI-Fc to its
ligands was compared with 9O12 using the same concentration
of 10 g/ml (Fig. 2). 9E18 reduced the binding of GPVI to
collagen by 45%, reduced the binding of GPVI to CRP by 85%,
but had little effect on binding to convulxin (25% inhibition). In
addition, inhibition of GPVI interaction with collagen by 9E18
was dose-dependent; the maximal inhibition reached 55% for
concentrations of 9E18 above 15 g/ml, and the IC50 was 1.6
g/ml (not shown). In contrast, 3F8 decreased the binding of
rsGPVI-Fc to convulxin by 55% and to CRP by 50%, but not the
binding to collagen (l0% inhibition, Fig. 2). 3F8 dose-depend-
ently inhibited GPVI interaction with convulxin with an IC50 of
0.5 g/ml. Maximal effect was reached with 5 g/ml antibody
and did not increase further with a higher concentration of 3F8
(not shown). In the presence of an isotype-matched control
antibody, 7I20, the binding of rsGPVI to neither collagen, con-
vulxin, nor CRP was affected (Fig. 2).
Cross-reactivity studies showed that 9O12, 9E18, and 3F8 did
not compete for the same binding site on rsGPVI-Fc; although
each antibody prevented its own binding to GPVI, the interaction
of the soluble receptor with one immobilized mAb was not im-
paired in the presence of the others (not shown). This indicated
that the three mAbs recognize distinct epitopes on GPVI.
Similar results were obtained when mAbs were tested on the
adhesion of rGPVI-HEL to GPVI ligands (not shown). 9O12 (20
g/ml) inhibited the adhesion of rGPVI-HEL to collagen by 70%
and completely prevented cell adhesion to CRP (17). 20 g/ml
9E18 reduced the adhesion of rGPVI-HEL to collagen by 35%.
In contrast, the adhesion of rGPVI-HEL to convulxin was
poorly affected by either 9O12 or 3F8, inhibition being only 25
and 10%, respectively. However, when cells were incubated
with both 9O12 and 3F8, a synergistic inhibitory effect was
observed that reached 65%. This might indicate that both
monoclonal antibodies bind to independent sites close to or
belonging to the convulxin-binding site. All three antibodies
abolished the binding of rGPVI-HEL to immobilized CRP by
more than 90% (not shown), consistent with the results ob-
tained when using rsGPVI-Fc (Fig. 2B).
Epitope Mapping of 9O12 Using Phage Display—Taken to-
gether, these results prompted us to focus our efforts on the
identification of the epitope of mAb 9O12 since this antibody
was the most efficient to prevent GPVI interactions with all its
FIG. 1. Competition between colla-
gen, CRP, and convulxin for binding
to cell expressed GPVI. rGPVI-HEL
cells were preincubated for 15 min at
room temperature with increasing doses
of collagen, convulxin, or CRP. Cells were
next allowed to adhere to immobilized li-
gand (collagen, CRP, or convulxin). Re-
sults are presented as follows: adhesion to
collagen in the presence of convulxin (A),
adhesion to convulxin in the presence of
collagen (B), or adhesion to CRP in the
presence of convulxin (C) or collagen (D).
Data are expressed as percentage of con-
trol, that is, the binding of rGVPI-HEL in
the absence of competing molecules, and
is given as mean  S.E. of n  three
independent experiments.
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ligands, including the physiological collagen. For this purpose,
we screened a combinatorial library of linear pentadecamer
peptides by phage display technology. After three rounds of
biopanning, 66 individual clones were obtained. 46 clones were
randomly selected and tested for their ability to bind to immo-
bilized 9O12 in ELISA. 12 were positive, as illustrated for three
clones on Fig. 3A. The binding of 9O12 to the phages was also
analyzed by Western blotting. 9O12 IgG recognized the phages
under non-reducing conditions, whereas disulfide bridge reduc-
tion greatly impaired the binding of 9O12 (Fig. 3C).
Importantly, rsGPVI-Fc competed with the selected phages
for the binding to 9O12 in ELISA (illustrated on Fig. 3B with
two clones), suggesting that the peptides displayed by the
phages mimic a structure found in GPVI. No binding of the
phages to other anti-GPVI mAbs (3F8, 3J24) was observed,
demonstrating the specificity of their interaction with 9O12.
Sequencing of these 12 clones resulted in the identification of
four sequences (Table I). All sequences share the motif
CGLXXVC. The presence of the two cysteines, together with
the fact that the binding of 9O12 to the peptides was impaired
upon disulfide bond reduction, strongly suggested that the
cysteines were forming a disulfide bridge and that a con-
strained conformation was required for recognition by 9O12.
This was consistent with our previous observation that the
epitope of 9O12 within GPVI is conformational (17).
The corresponding cyclic peptides were synthesized for func-
tional analysis. Unfortunately, these were not soluble, and all
our attempts to solubilize them remained unsuccessful, even
after various modifications. We therefore chose a different ap-
proach and used computer modeling of GPVI to identify candi-
date residues for site-directed mutagenesis.
Epitope Mapping of 9O12 Using Homology Modeling of GPVI
Structure—The peptide sequences of the clones were aligned to
the sequence of the extracellular domain of human GPVI. The
motif CGLXXVC could not be found as such in the sequence of
GPVI, and no obvious similarity was identified. However, we
noticed a relative homology with region 30–40 of GPVI, and
particularly, the presence of a glycine, a valine, and a leucine in
the vicinity of a cysteine in position 28 (Table I).
We used homology modeling to produce a structure of the EC
domains of human GPVI. We observed that a loop located at an
end of the IgC2-1 domain presented three residues found in the
motif: Gly-30, Val-34, and Leu-36. These were in close vicinity,
in a constrained environment, and apparently exposed at the
surface of the protein, accessible to ligand (Fig. 4). Therefore,
we hypothesized that these residues could be involved in col-
lagen recognition.
To test this hypothesis, we produced mutants of rsGPVI-Fc
in which Gly-30, Val-34, and Leu-36 were altered to alanine.
Three variants were constructed: two consisting of point mu-
tations, V34A and L36A, and one in which the three residues
were simultaneously mutated, G30A,V34A,L36A.
Mutation of Val-34 and Leu-36 Inhibits the Binding of GPVI
to Collagen and CRP—Mutants V34A, L36A, and
G30A,V34A,L36A displayed an apparent molecular weight, de-
termined in SDS-PAGE, identical to that of WT rsGPVI-Fc.
They were recognized by a non-inhibitory anti-GPVI mAb
(3J24) binding to WT rsGPVI-Fc in Western blot, indicating
that proteins were correctly expressed.
We measured the binding properties of 9O12 to immobilized
rsGPVI-Fc mutants (2 g/ml). None of the mutations affected
the maximal binding of the antibody. The affinity of 9O12 for
L36A was comparable with that measured for WT rsGPVI-Fc
(Kd  0.079 versus 0.075 g/ml) (Table II). However, the affin-
ity of 9O12 for V34A was significantly decreased by a factor of
1.6 (Kd  0.125 g/ml), as was the affinity of the antibody for
the triple mutant (Kd  0.127 g/ml).
The ability of each mutant to bind to immobilized GPVI li-
gands was then investigated. WT rsGPVI-Fc dose-dependently
bound to immobilized collagen with an apparent Kd of 1.2  0.2
g/ml (Fig. 5A). The L36Amutation slightly reduced the capacity
of GPVI to bind to collagen; the Kd was of 3.6  0.2 g/ml.
Mutation of Val-34 was far more effective and strongly impaired
GPVI interaction with collagen. The apparent Kd increased to
22  2 g/ml. The triple mutation G30A,V34A,L36A yielded full
inhibition of the binding to collagen.
WT rsGPVI-Fc bound to immobilized CRP in a dose-depend-
ent manner, with an apparentKd of 0.8 0.1 g/ml comparable
with that measured on collagen (Fig. 5B). Mutation of Leu-36
did not impair the ability of GPVI to interact with CRP; the
resulting affinity was identical to that measured with WT
rsGPVI-Fc (Kd  1  0.2 g/ml). Mutation of Val-34, on the
other hand, markedly reduced the affinity of GPVI toward
CRP; the Kd increased to 6.5  1 g/ml. Again, simultaneous
mutation of Gly-30, Val-34, and Leu-36 resulted in full inhibi-
tion of the binding to CRP. The Kd increased up to 70  5
g/ml. None of the mutations reduced the binding of rsGPVI-Fc
to immobilized convulxin (data not shown).
FIG. 2. Selective inhibition of GPVI interactions with its ligands by anti-GPVI mAbs. rsGPVI-Fc was preincubated with anti-GPVI
mAbs 9O12, 9E18, or 3F8, or with irrelevant isotype-matched mAb 7I20 (10 g/ml each) for 30 min at room temperature. Immune complexes were
then added to collagen- (A) or CRP- (B) coated wells and incubated 30 min. After washing, bound rsGPVI-Fc was detected using protein A-HRP.
C, alternatively, coated rsGPVI-Fc was incubated for 45 min with 9O12, 9E18, 3F8, or 7I20 (10 g/ml each), after which 125I-convulxin was added,
and incubated for 10 min. Bound 125I-convulxin was measured by  counting. Data are given as mean  S.E. of n  four independent experiments.
*, p  0.05; **, p  0.01; ***, p  0.001.
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We further analyzed the effect of the mutations on GPVI
function by testing the ability of the variants to compete with
platelet GPVI and to inhibit collagen-induced platelet aggrega-
tion (Fig. 6). As already reported elsewhere (3), preincubation
of WT rsGPVI-Fc with collagen completely prevented platelet
aggregation. Mutant L36A similarly inhibited collagen-induced
aggregation. In contrast, the V34A and the triple mutation
almost completely reversed the inhibitory effect of rsGPVI-Fc
on collagen-induced platelet aggregation. The fact that V34A
and G30A,V34A,L36A could hardly prevent platelet activation
by collagen correlated well with their respective loss of affinity
toward collagen measured in ELISA.
DISCUSSION
We describe here the characterization of ligand-binding sites
in human GPVI using newly developed tools. GPVI is critically
involved in collagen-induced platelet activation and thrombus
formation following vascular injury (25). Although GPVI has
been cloned (2, 3), little is known about the structure of its
ligand-binding site. Whereas KIR family members bind their
HLA ligands in the interdomain (EC1–EC2) region of the re-
FIG. 3. Selection and characterization of phage clones binding to 9O12. A, dose-dependent binding of phage clones E9 (●), G9 (Œ), B12
(), and irrelevant phage (f) to immobilized 9O12. Bound phages were detected using polyclonal anti-M13-HRP antibodies. B, inhibition of the
binding of phage clone G8 (●) and B12 (Œ) to immobilized 9O12 by rsGPVI-Fc. Increasing doses of rsGPVI-Fc were incubated with immobilized
9O12 for 15 min at room temperature. Phages (clones G8 and B12, 1.5  109 each) were added to the wells and incubated for 1 h. Bound phages
were detected as described above. C, proteins from purified phages B12, E9, and G9 (21010) were analyzed in SDS-PAGE using a 10% slab gel
under non-reducing (NR) and reducing (R) conditions. Proteins were transferred to a nitrocellulose membrane, and detection was performed using
biotinylated 9O12 (2 g/ml in PBS, 0.4% milk powder) followed by incubation with streptavidin-HRP.
TABLE I
Peptide sequence of the phage clones selected by anti-GPVI mAb 9O12
Alignment of selected peptide sequences with region 21–40 of the
human GPVI EC1 domain. The consensus motif and corresponding
residues within GPVI are indicated in bold.






FIG. 4. Location of 9O12 epitope within human GPVI. Residues
forming the putative epitope of 9O12 in a homology model of human
GPVI are shown. The structure of human GPVI is based on the crys-
tallographic data of the human LIR binding site (see “Experimental
Procedures”). Hypothesized epitope residues are represented as space-
filling atoms in the whole molecule, represented as a ribbon frame.
Lys-59 involved in CRP binding (28) is represented in brown.
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ceptor, the IgA-binding site on FcRI involves structures in the
EC1 domain at a distance from the hinge region (14, 15).
To characterize GPVI interactions with its ligands, we used
two complementary approaches. First, we performed a static
adhesion assay, using a hematopoietic cell line overexpress-
ing human GPVI (rGPVI-HEL) to determine whether colla-
gen, CRP, and convulxin could compete with one another for
the binding to cell-expressed GPVI. Second, we have ana-
lyzed a panel of mAbs directed against the extracellular
domain of human GPVI and measured their effect on the
binding of a recombinant soluble form of human GPVI
(rsGPVI-Fc) to its ligands. This led to the identification of
three mAbs 9O12, 9E18, and 3F8 with selective inhibitory
properties. Together the results obtained indicated that the
diverse GPVI ligands interact with binding sites exhibiting
specific features but also sharing some residues participating
in the recognition of these ligands.
This assertion is supported by several observations that
follow. (i) Collagen and convulxin compete with each other
and with CRP for the binding to GPVI. (ii) mAbs 9O12 and
9E18 both inhibit GPVI interaction with collagen but recog-
nize independent epitopes on GPVI, and the same is observed
for 9O12 and 3F8 on GPVI interaction with convulxin. (iii)
Only the combination of 9O12 and 3F8 could strongly impair
the binding of cell-expressed GPVI to convulxin. Collagen-
and convulxin-binding sites thus exhibit distinct features but
might also share common residues and be overlapping since
9O12 can prevent GPVI interactions with both ligands. The
CRP-binding site is likely to be part of the collagen-binding
site. Not only are these multimeric peptides built around the
GPO motif derived from the sequence of collagen (18), but
collagen and CRP compete with each other for the binding to
GPVI. Schulte et al. (26) reported that the inhibitory effect of
JAQ1, a mAb blocking the CRP-binding site on mouse GPVI,
on collagen-induced platelet activation could be overcome by
increasing concentrations of collagen. Our results are consist-
ent with these data. However, since in addition convulxin
fully prevents rGPVI-HEL adhesion to CRP, this site could be
located in the vicinity of the convulxin-binding site or might
share common structures with it. Despite the high affinity of
the ligand, the interaction of GPVI with CRP is easily dis-
rupted by the binding of anti-GPVI mAbs. This suggests that
conformational changes within GPVI may be induced by in-
teractions with antibodies or other ligands and may drasti-
cally reduce the accessibility of the CRP-binding site.
9O12 was of particular interest since it inhibits the interac-
tion of GPVI with all its ligands and efficiently blocks all
collagen- and CRP-induced platelet responses in vitro (17). We
thus focused our efforts on the identification of its epitope.
Preliminary experiments showed that 9O12 only bound to
GPVI in non-reducing conditions, suggesting that its epitope
involves a disulfide bridge-maintained structure. By screening
a pentadecamer phage display peptide library, we have identi-
fied phages that specifically compete with rsGPVI-Fc for the
binding to immobilized 9O12. Sequencing of those peptides
revealed a consensus motif: CGLXXVC. The presence of two
cysteines, together with the fact that 9O12 poorly recognized
TABLE II
Affinity of mAb 9O12 towards rsGPVI-Fc mutants
The binding of 9O12 to immobilized rsGPVI-Fc (wild type or mutants,
2 g/ml each) was measured. Detection of bound 9O12 was performed
using goat anti-mouse antibody coupled to HRP followed by colorimetric
reaction with ortho-phenylenediamine dihydrochloride. Association
curves were drawn, and Kd was determined for each interaction. Re-
sults are given as mean  S.E. of three independent experiments. NS,
not significant.




Wild type 0.079  0.006
L36A 0.075  0.001 NS
V34A 0.125  0.002 p  0.001
G30A,V34A,L36A 0.127  0.010 p  0.001
FIG. 5. Binding of rsGVI-Fc mutants to immobilized collagen
and CRP. Wild type rsGPVI-Fc () and mutant rsGPVI-Fc V34A (●),
L36A (f), and G30A,V34A,L36A (Œ) were incubated with immobilized
collagen (1 g) (A) or CRP (0.5 g) (B) for 2 h. After washing, bound
rsGPVI-Fc was detected using protein A-HRP and subsequent colori-
metric reaction. Data are given as mean  S.E. of three independent
experiments.
FIG. 6. Inhibition of collagen-induced platelet aggregation by
rsGPVI-Fc mutants. Human washed platelets (3.108/ml) were acti-
vated by 0.5 g/ml collagen. Collagen was preincubated with buffer,
with V34A, L36A, G30A,V34A,L36A, or wild type rsGPVI-Fc (10 g
each), for 5 min at 37 °C before addition to platelets. The aggregation
curves shown are representative of duplicates from three independent
experiments.
Collagen-binding Site on Human GPVI52298
the peptides under reducing conditions, suggested that the
cysteines formed a disulfide bridge and that such constrained
structure is required for 9O12 binding. As expected, direct
alignment of the peptides with the sequence of human GPVI
did not lead to the identification of a linear epitope but allowed
the localization of several amino acids found in the consensus
motif that were in close vicinity in the GPVI sequence: Gly-30,
Val-34, and Leu-36. Homology modeling of the structure of
GPVI showed that these residues were exposed at the surface
of the receptor and located in a loop within the EC1 domain.
By site-directed mutagenesis, we generated variants of
rsGPVI-Fc in which the selected residues were altered to ala-
nine: V34A, L36A, and G30A,V34A,L36A. The characterization
of the mutants showed that Val-34 and, to a lesser extent,
Leu-36 are critically involved in GPVI interaction with collagen
and CRP. By itself, the substitution V34A caused a major
inhibition of the binding of GPVI to immobilized collagen and
CRP. The triple mutation virtually abolished the binding to
both ligands. Furthermore, V34A and G30A,V34A,L36A had a
severely impaired ability to prevent collagen-induced platelet
activation as compared with wild type rsGPVI-Fc. This loss of
inhibitory effect nicely correlated with the decreased affinity of
these variants for collagen. Mutation of Val-34 and the triple
mutation similarly altered GPVI interaction with both collagen
and CRP, confirming that the two ligands bind to common
sites. In contrast, 9O12 still bound to the mutants, although its
affinity for V34A and the triple mutant is significantly de-
creased. This suggests that residues other than Val-34 and
Leu-36 are part of the 9O12 epitope.
The scFv antibody 10B12, another antagonist of human
GPVI function, is thought to map to the CRP-binding site (27).
It has recently been shown, using molecular modeling of hu-
man GPVI and 10B12, along with site-directed mutagenesis,
that lysine 59 in EC1 (Fig. 4, in brown) was critically involved
in the binding to CRP, with a minor contribution of residues
arginine 166 and arginine 117 located in the hinge region and
EC2 domain of the receptor (28). In this study, the authors
suggested the existence of two CRP-binding sites of different
affinity. Whether the motif in the EC1 domain we have iden-
tified is the secondary CRP-binding site is plausible.
In conclusion, we have identified a site within GPVI critically
involved in recognition of collagen and CRP. This locus com-
prises Val-34 and Leu-36 and is located in the first IgC2 do-
main, at a distance from the potential CRP-binding site de-
scribed by Smethurst et al. (28), in the hinge region of the
receptor. The collagen-binding site thus appears to be wide-
spread and to cover a larger surface on GPVI.
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